2271119-26-5
2271119-26-5 structure
- Name: CSF1R-IN-2
- Chemical Name: CSF1R-IN-2
- CAS Number: 2271119-26-5
- Molecular Formula: C20H20FN7O2
- Molecular Weight: 409.42
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK c-Fms
- Create Date: 2019-06-01 20:09:05
- Modify Date: 2026-07-01 19:38:54
-
CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively[1].
| Name | CSF1R-IN-2 |
|---|---|
| Synonyms |
Elzovantinib (TPX-0022)
TPX-0022 Elzovantinib Elzovantinib (TPX-0022, CSF1R-IN-2) colony stimulating factor 1 rector,CSF-1R,CSF1R IN 2,inhibit,CSF1RIN2,c-Met/HGFR,CSF1R,CSF-1R-IN-2,Inhibitor,CSF-1 rector,Src,c-Fms CSF1R inhibitor 2 (S)-12-Amino-2-ethyl-45-fluoro-6-methyl-9-oxo-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphane-46-carbonitrile 1,15-Etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile, 3-amino-14-ethyl-11-fluoro-4,5,6,7,13,14-hexahydro-7-methyl-4-oxo-, (7S) TPX-0022(CSF1R-IN-2) CSF1R-IN-2, 10 mM in DMSO Elzovantinib (TPX-0022) ，S9620 |
| Description | CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.12 nM (SRC), 0.14 nM (MET), 0.76 nM (c-FMS)[1]. |
| In Vitro | CSF1R-IN-2 (compound 5) causes the suppression of MET autophosphorylation as well as the downstream STAT3, ERK and AKT phosphorylation at IC50 values of around 1-3 nM in SNU-5 and MKN-45 cell lines[1]. |
| In Vivo | CSF1R-IN-2 (compound 5: p.o., BID, 13 days) treatment results in an 85% tumor regression and no body weight loss is observed after 21 days treatment in mice[1]. CSF1R-IN-2 (compound 5: p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively in SCID/Beige mice[1]. CSF1R-IN-2 (compound 5) inhibits MET activity in MKN-45 tumors following oral administration in mice[1]. Animal Model: Mice bearing LU2503 tumors patient derived xenograft (PDX) NSCLC model[1]. Dosage: 15 mg/kg. Administration: PO, BID (twice daily) for 13 days. Result: Resulted in an 85% tumor regression and no body weight loss was observed after 21 days treatment. Animal Model: SCID/Beige mice bearing Ba/F3 ETV6-CSF1R tumors with average tumor size of ~180 mm3[1]. Dosage: 5 and 15 mg/kg. Administration: PO, BID (twice daily) for 10 days. Result: Demonstrated the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively. |
| References |
[1]. WO 2019023417 A1. |
| Molecular Formula | C20H20FN7O2 |
|---|---|
| Molecular Weight | 409.42 |